IBRX — ImmunityBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1326110 ·
Last close
$8.22
Market Cap
$8.61B
52W High
$9.60
52W Low
$6.68
ADV30
13,242,913
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 44,206,000 | 43,968,000 | -69,791,000 | -632,782,000 | 646,637,000 | 205,194,000 | 1,515,763,000 |
| Dec 2025 | 38,285,000 | 37,903,000 | -64,683,000 | -61,944,000 | 501,898,000 | 88,334,000 | 1,001,472,000 |
| Sep 2025 | 32,061,000 | 31,884,000 | -55,630,000 | -67,253,000 | 518,987,000 | 60,241,000 | 1,042,397,000 |
| Jun 2025 | 26,425,000 | 26,289,000 | -71,285,000 | -92,555,000 | 402,076,000 | 137,658,000 | 971,895,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-304,936,000
Investing CF
$-149,801,000
Financing CF
$400,241,000
CapEx
$-4,252,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,726,646,000
Inventory
$910,000
Receivables
$42,617,000
ST Investments
$154,484,000
EBIT TTM
$-239,082,000
Pretax Income TTM
$-351,607,000
Interest Exp TTM
$112,525,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$140,976,992
EBITDA
$-245,412,992
Free Cash Flow
$-193,704,624
Enterprise Value
$10,034,638,848
Total Cash
$380,879,008
Total Debt
$1,124,608,000
Shares Out
1,047,353,977
Trailing EPS
$-0.85
Book Value
$-0.83
ROE
—
ROA
-34.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 113,288,000 | -256,027,000 | -351,398,000 | 501,898,000 | 1,001,472,000 | — | -304,936,000 |
| Dec 2024 | 14,745,000 | -344,182,000 | -413,564,000 | 382,933,000 | 871,062,000 | — | -391,236,000 |
| Dec 2023 | 622,000 | -361,364,000 | -583,196,000 | 504,452,000 | 1,090,389,000 | — | -366,757,000 |
| Dec 2022 | 240,000 | -350,617,000 | -416,567,000 | 362,356,000 | 812,176,000 | — | -337,509,000 |
TTM Snapshot
Revenues TTM
$6,372,000
NetIncome TTM
$-379,878,000
OpCashFlow TTM
$0
Assets (Latest)
$382,933,000
Forward EPS
$0.06
Max Pain — expiry 2026-07-17
max pain strike: $7.50 · spot: $8.22 · call oi: 70,274 · put oi: 33,798
Expected Move to 2026-07-17:
±$0.88
(10.64%) —
implied range
$7.35 –
$9.10
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $8.56B | $41.51 | — |
| PCVX | Vaxcyte, Inc. | $8.41B | $58.21 | — |
| APGE | Apogee Therapeutics, Inc. | $8.25B | $133.65 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.04B | $76.20 | — |
| IMVT | Immunovant, Inc. | $8.15B | $39.71 | — |
News headlines (Yahoo Finance, 1h cache)
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
2026-07-10 16:04 · Yahoo
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise
2026-07-10 07:53 · Yahoo
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst
2026-07-06 05:57 · Yahoo
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales
2026-06-30 01:39 · Yahoo
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
2026-06-29 11:56 · Yahoo
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology
2026-06-29 04:24 · Yahoo
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes
2026-06-26 17:42 · Yahoo
IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying
2026-06-24 02:17 · Yahoo
Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller
2026-06-19 13:35 · Yahoo
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026
2026-06-11 01:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.